Phio Pharmaceuticals signs manufacturing agreement for cancer drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- Wall St futures fall as chip stocks resume slide after Micron-led rally
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
March 30, 2026 7:02 AM EDTA Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous Carcinomas
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compound PH-762 for both clinical trial and commercial supply.
"It is a... More
